Clinical trial
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
NCT00339144 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00339144 |
|---|---|
| Title | Study of Dasatinib (BMS-354825) in Patients With Solid Tumors |
| Official title | A Phase I Study of BMS-354825 in Patients With Solid Tumors |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 16 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jun 20, 2006 |
| Last update posted | Dec 15, 2010 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: